文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

外泌体微小RNA调控急性肺损伤/急性呼吸窘迫综合征发病机制的研究进展

[Research advances of exosomal micrornas in regulating the pathogenesis of acute lung injury/acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论综述指出外泌体miRNA通过调控肺泡上皮细胞、内皮细胞、巨噬细胞和中性粒细胞的自噬、焦亡、凋亡及炎症信号等过程,加重或减轻急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)进展。

急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)起病急、病死率高,当前治疗以支持性为主,对预后改善有限。外泌体miRNA(40-150 nm的细胞外囊泡内含非编码单链RNA)可在细胞间传递蛋白质、核酸和miRNA,参与ALI/ARDS病理生理。在ALI/ARDS模型中,外泌体miRNA递送至肺泡上皮细胞、内皮细胞、巨噬细胞和中性粒细胞,调控自噬、焦亡、凋亡、增殖、炎症信号、巨噬细胞极化和中性粒细胞活化,从而加重或减轻疾病进展。工程化技术可克服天然外泌体的局限,增强外泌体miRNA的治疗潜力。本文综述外泌体miRNA在关键细胞类型中调控ALI/ARDS发病机制的研究进展,为新型治疗策略提供思路。

要点

  • 外泌体miRNA是40-150 nm细胞外囊泡内的非编码单链RNA,可在细胞间传递并调控ALI/ARDS病理过程。
  • 在ALI/ARDS模型中,外泌体miRNA递送至肺泡上皮细胞、内皮细胞、巨噬细胞和中性粒细胞,调控自噬、焦亡、凋亡、增殖、炎症信号、巨噬细胞极化和中性粒细胞活化。
  • 外泌体miRNA对ALI/ARDS进展具有加重或减轻的双向作用。
  • 工程化技术可克服天然外泌体的局限,增强外泌体miRNA的治疗潜力。
  • 当前ALI/ARDS管理仍以支持性治疗为主,对症缓解但预后改善有限,需深入探索上游致病机制以寻找更安全有效的疗法。

适用人群与场景

  • ALI/ARDS由直接/间接肺相关或全身性触发因素引起,导致肺上皮细胞和内皮细胞广泛损伤。

处置流程与药物剂量

  • 当前ALI/ARDS管理仍以支持性治疗为主,提供对症缓解但对预后改善有限。

研究设计与关键结果

  • 综述聚焦外泌体miRNA在ALI/ARDS关键细胞类型(肺泡上皮细胞、内皮细胞、巨噬细胞、中性粒细胞)中调控发病机制的作用,为新型治疗策略提供见解。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,深入探索ALI/ARDS上游致病机制有助于识别更安全、更有效的疗法。
  • 作者认为,工程化技术通过克服天然外泌体的局限,增强了外泌体miRNA的治疗潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a severe critical condition marked by rapid progression and high fatality. It results from direct/indirect lung-related or systemic triggers, leading to widespread injury of lung epithelial and endothelial cells. Its pathogenesis involves uncontrolled inflammation and breakdown of the lung's blood-air barrier due to leaky blood vessels and epithelial damage. Current management of ALI/ARDS remains primarily supportive, offering symptomatic relief but limited improvement in prognosis, necessitating deeper exploration of upstream pathogenic mechanisms to identify safer and more effective therapies. Exosomal microRNAs (miRNA), small extracellular vesicles (40-150 nm) containing non-coding single-stranded RNAs, regulate post-transcriptional cellular processes and participate in ALI/ARDS pathophysiology. Studies reveal that exosomes transport proteins, nucleic acids, and miRNAs to recipient cells, mediating intercellular communication. In ALI/ARDS models, exosomal miRNAs delivered to alveolar epithelial cells, endothelial cells, macrophages, and neutrophils critically modulate autophagy, pyroptosis, apoptosis, proliferation, inflammatory signaling, macrophage polarization, and neutrophil activation, either exacerbating or alleviating disease progression. Recent advances in engineering techniques have enhanced the therapeutic potential of exosomal miRNAs by overcoming limitations of natural exosomes. This review focuses on exosomal miRNA-mediated regulation of ALI/ARDS pathogenesis across key cell types, providing insights for novel therapeutic strategies.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen L, Lyu J, Zhang X, et al. [Research advances of exosomal micrornas in regulating the pathogenesis of acute lung injury/acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40819952. doi:10.3760/cma.j.cn121430-20240802-00659

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。